AstraZeneca Shares at $204.76; 8.43% Monthly Gain, 37.48% Yearly Rise, Fund Highlights Trial Wins
Carillon Eagle Fund added AstraZeneca to its top five Q4 holdings, noting shares closed at $204.76 and returned 8.43% monthly and 37.48% annually. The company beat Q3 estimates, reaffirmed 2026 margin improvement guidance, struck a constructive drug pricing agreement and reported positive hypertension trial results.
1. Fund Letter Spotlights AstraZeneca
Carillon Eagle Growth & Income Fund, with net assets of $493.06 million across 48 holdings, named AstraZeneca among its top five contributors in its fourth-quarter 2025 investor letter, highlighting its material impact on the fund’s performance.
2. Strong Share Gains
AstraZeneca shares closed at $204.76 on February 11, achieving an 8.43% return over the past month and a 37.48% increase over the last 52 weeks, underpinning its $317.436 billion market capitalization.
3. Operational Beat and Clinical Progress
In the third quarter, AstraZeneca surpassed analyst revenue and profit forecasts, reaffirmed its operating margin improvement outlook for 2026, secured a constructive drug pricing agreement with the U.S. administration, and released positive Phase III trial data for a new hypertension treatment expected by mid-2026.